Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Etoposide 34Carboplatin 31Topotecan 24Cisplatin 21atezolizumab 11PM 01183 8durvalumab 7Irinotecan 7amrubicin 5PE regimen 4AMG 757 4rovalpituzumab tesirine 3pembrolizumab 3Magnetic Resonance Spectroscopy 3Dexamethasone 3tremelimumab 2tislelizumab 2etoposide phosphate 2apatinib 2Vitamin E 2Tiragolumab 2Specimen Handling 2Radiosurgery 2RRx-001 2Paclitaxel 2Memantine 2Injections 2EC regimen 2trilaciclib 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Small Cell Lung Carcinoma × obatoclax × Clear all
NCT01563601 2012-08-15

Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡